A randomised clinical trial investigating the effect of dalcetrapib versus placebo in patients with recent acute coronary syndrome
Studied treatment | dalcetrapib 600 mg daily beginning 4 to 12 weeks after an index ACS event |
Control treatment | placebo |
Concomittant treatment | individualized, evidence-based programs for lowering their LDL cholesterol levels by means of statin therapy (if they did not have unacceptable side effects) and diet, with a target LDL cholesterol level of 2.6 mmol per liter or lower and preferably 1.8 mmol per liter or lower. |
Patients | patients with recent acute coronary syndrome |
Group sizes | 7938 / 7933 |
Blindness | double-blind | Inclusion period | Apr 2008 - Jul 2010 |
Follow-up duration | 31 montsh (median) | Centers | 935 |
Lost to FU | geographical localisation | 27 countries | |
Primary endpoint | CV events | Design | Parallel groups |
PeriodeInclusion | Apr 2008 - Jul 2010 |
Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009 Dec;158:896-901.e3 [PMID: 19958854] link to pdf add to Mendeley
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 2012 Nov 5;: [PMID: 23126252] link to pdf add to Mendeley
Links
ClinicalTrial.gov record NCT00658515
Appears in following systematic reviews: